An Exploratory, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Subjects With Major Depressive Disorder
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Seltorexant (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2018 Planned End Date changed from 7 Jan 2019 to 6 May 2019.
- 12 Jan 2018 Status changed from not yet recruiting to recruiting.